Cepheid

Xpert MTB/RIF: Introduction, Principle, Procedure, Result-Interpretation, Uses, and Keynotes

by
GeneXpert® Xpert® MTBRIF Test Result- MTB Detected (Very Low) and Rifampicin Resistance Not Detected

Introduction The Xpert MTB/RIF assay is an automated, cartridge-based molecular test used to detect Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance, the most potent first-line anti-TB drug. Endorsed by the WHO in 2010, the Xpert MTB/RIF assay revolutionized TB diagnosis by providing results in less than two …

Read more

Xpert MTB/RIF Ultra: Introduction, Principle, Procedure, Result-Interpretation, Uses, and Keynotes

by
GeneXpert Dx System software interface displaying a completed diagnostic result for an Xpert MTB-RIF Ultra assay

Introduction Xpert MTB/RIF Ultra is an automated diagnostic test designed for the rapid and simultaneous detection of Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF). It is a second-generation assay developed by Cepheid to provide significantly higher sensitivity than the original Xpert MTB/RIF, particularly for …

Read more

Xpert MTB-XDR: Introduction, Principle, Procedure, Result-Interpretation, Uses, and Keynotes

by
The image shows a GeneXpert software interface displaying an Xpert MTB/XDR test result with M. tuberculosis (MTB) detected and a specific drug resistance profile.Key Findings:MTB DETECTED: Positive for Mycobacterium tuberculosis complex.Low FLQ Resistance DETECTED: Indicates low-level resistance to fluoroquinolones (e.g., levofloxacin or moxifloxacin).Resistance NOT DETECTED: No mutations were found for isoniazid (INH), amikacin (AMK), kanamycin (KAN), capreomycin (CAP), or ethionamide (ETH).This result is consistent with a pre-XDR-TB diagnosis, as there is resistance to fluoroquinolones but susceptibility to second-line injectables.

Introduction The Xpert MTB/XDR assay is an advanced molecular diagnostic tool designed by Cepheid to rapidly detect Mycobacterium tuberculosis complex (MTBC) and its resistance to multiple first- and second-line drugs. Launched in 2021, it is categorized as a “low complexity” automated nucleic acid amplification test …

Read more